Metabolic consequences of modern immunosuppressive agents in solid organ transplantation

Therapeutic Advances in Endocrinology and Metabolism

Volumn 7, Issue 3, 2016, Pages 110-127

  Bamgbola, Oluwatoyin ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Immunosuppressive therapy; Metabolic adverse effects; Solid organ transplants

Indexed keywords

BELATACEPT; CALCINEURIN INHIBITOR; CYCLOSPORIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; RAPAMYCIN; STEROID; TACROLIMUS;

BONE DISEASE; BONE METABOLISM; CARDIOVASCULAR MORTALITY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DYSLIPIDEMIA; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; GLUCONEOGENESIS; GLUCOSE INTOLERANCE; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HUMAN; HYPERLIPIDEMIA; LYMPHOCYTE PROLIFERATION; METABOLIC ACTIVATION; MICROANGIOPATHY; NEPHROTOXICITY; OBESITY; ORGAN TRANSPLANTATION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84973333938     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018816641580     Document Type: Review

References (139)

1. M.Bailey, J.Mullins, C.Kenyon (2009) Mineralocorticoid and glucocorticoid receptors stimulate epithelial sodium channel activity in a mouse model of Cushing syndrome. Hypertension 54: 890–896.
2. F.BakarK.KevenB.DogruF.AktanS.ErturkA.Tuzuner. (2009) Low-density lipoprotein oxidizability and the alteration of its fatty acid content in renal transplant recipients treated with cyclosporine/tacrolimus. Transplant Proc41:1630–1633.
3. M.BaumO.Moe (2008) Glucocorticoid-mediated hypertension: does the vascular smooth muscle hold all the answers?J Am Soc Nephrol19: 1251–1253.
4. M.BenfieldS.BartoshD.IkleB.WarshawN.BridgesY.Morrison. (2010) Randomized double-blind, placebo controlled trial of steroid withdrawal after pediatric renal transplantation. Am J Transplant10: 81–88.
5. H.BergremT.ValderhaugA.HartmannH.BergremJ.HjelmesaethT.Jenssen (2010) Glucose tolerance before and after renal transplantation. Nephrol Dial Transplant25: 985–992.
6. R.BloomP.Reese (2007) Chronic kidney disease after nonrenal solid-organ transplantation. J Am Soc Nephrol18: 3031–3041.
7. S.BoschettiP.NogueiraA.PereiraM.FisbergJ.Pestana (2013) Prevalence, risk factors, and consequences of overweight in children and adolescents who underwent renal transplantation – Short- and medium-term analysis. Pediatr Transplant17: 41–47.
8. V.BrinerG.ThielM.Monier-FaugereB.BognarJ.LandmannV.Kamber. (1995) Prevention of cancellous bone loss but persistence of renal bone disease despite normal 1,25 vitamin D levels two years after kidney transplantation. Transplantation59: 1393–1400.
9. K.BuddeT.BeckerW.ArnsC.SommererP.ReinkeU.Eisenberger. (2011) Everolimus- based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet377: 837–847.
10. F.BurkhalterT.OettlB.DescoeudresA.BachmannL.GuerkeM.Mihatsch. (2012) High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study. Transplant Proc44: 2961–2965.
11. L.CalòP.DavisB.GiaconE.PagninM.SartoriP.Riegler. (2002) Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: effect of ramipril. J Cardiovasc Pharmacol40: 625–631.
12. E.CanalisG.MazziottiA.GiustinaJ.Bilezikian (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int18: 1319–1328.
13. M.CaseyH.Meier-Kriesche (2011) Calcineurin inhibitors in kidney transplantation: friend or foe?Curr Opin Nephrol Hypertens20: 610–615.
14. L.ChanA.AndresS.BunnapradistK.GugliuzzaR.ParasuramanV.Peddi. (2012) Renal function and NODM in de novo renal transplant recipients treated with standard and reduced levels of tacrolimus in combination with ECMPS. J Transplant2012: 941640.
15. D.ChhabraA.SkaroJ.LeventhalP.DalalG.ShahE.Wang. (2012) Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Clin J Am Soc Nephrol7: 504–512.
16. S.ChoiJ.Jin Sun JangS.HongD.JunS.Park (2006) Exercise and dexamethasone oppositely modulate B-cell function and survival via independent pathways in 90% pancreatectomized rats. J Endocrinol190: 471–482.
17. G.ChenJ.GuJ.QiuC.WangJ.FeiS.Deng. (2013) Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function. Exp Clin Transplant11: 310–314.
18. K.ClaesH.Meier-KriescheJ.ScholdY.VanrenterghemP.HalloranH.Ekberg (2012) Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. Nephrol Dial Transplant27: 850–857.
19. E.ColeG.PrasadC.CardellaJ.KimK.TinckamD.Cattran. (2013) A pilot study of reduced dose cyclosporine and corticosteroids to reduce new onset diabetes mellitus and acute rejection in kidney transplant recipients. Transplant Res2: 1. PMID: 23369458. DOI: 10.1186/2047144021.
20. F.CosioY.KudvaM.van der VeldeT.LarsonS.TextorM.Griffin. (2005) New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int67: 2415–2421.
21. M.DenburgM.PradhanJ.ShultsA.JonesJ.PalmerH.Baluarte. (2010) Longitudinal relations between obesity and hypertension following pediatric renal transplantation. Pediatr Nephrol25: 2129–2139.
22. K.DerflerM.HaydeG.HeinzM.HirschlG.StegerA.Hauser. (1991) Decreased postheparin lipolytic activity in renal transplant recipients with cyclosporin A. Kidney Int40: 720–727.
23. G.DuneaS.NakamotoR.StraffonJ.FigueroaA.VersaciM.Shibagaki. (1965) Renal homotransplantation in 24 Patients. Brit Med J1: 7–13.
24. B.EinollahiM.MotalebiM.SalesiM.EbrahimiM.Taghipour (2014) The impact of cytomegalovirus infection on new-onset diabetes mellitus after kidney transplantation: a review on current findings. J Nephropathol3: 139–148.
25. H.EkbergH.Tedesco-SilvaA.DemirbasS.VítkoB.NashanA.Gürkan. (2007) ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med357: 2562–2575.
26. P.Evenepoel (2013) Recovery versus persistence of disordered mineral metabolism in kidney transplant recipients. Semin Nephrol33: 191–203.
27. J.FerrarisP.ArgibayL.CostaG.JimenezP.CocciaL.Ghezzi. (2011) Influence of CYP3A5 polymorphism on tacrolimus maintenance doses and serum levels after renal transplantation: age dependency and pharmacological interaction with steroids. Pediatr Transplant15: 525–532.
28. J.FerrarisT.PasqualiniG.AlonsoS.LegalP.SorrocheA.Galich. (2007) Deflazacort Study Group. Effects of deflazacort vs. methylprednisone: a randomized study in kidney transplant patients. Pediatr Nephrol22: 734–741.
29. B.FosterK.MartzM.GowrishankarD.StableinA.Al-Uzri (2010) Weight and height changes and factors associated with greater weight and height gains after pediatric renal transplantation: A NAPRTCS study. Transplantation89: 1103–1112.
30. M.GallagherB.HallJ.CraigG.BerryD.TillerJ.Eris (2004) A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation78: 1653–1660.
31. M.GhantaM.KozickyB.Jim (2015) Pathophysiologic and treatment strategies for cardiovascular disease in end-stage renal disease and kidney transplantations. Cardiol Rev23: 109–118.
32. D.GnattaE.KeitelI.HeineckB.CardosoA.RodriguesK.Michel. (2010) Use of tacrolimus and the development of posttransplant diabetes mellitus: a Brazilian single-center, observational study. Transplant Proc42: 475–478.
33. S.GourishankarS.GrebeT.Mueller (2013) Prediction of kidney graft failure using clinical scoring tools. Clin Transplant27: 517–522.
34. Y.GueguenL.FerrariM.SouidiA.BattC.LuttonG.Siest. (2007) Compared effect of immunosuppressive drugs cyclosporine A and rapamycin on cholesterol homeostasis key enzymes CYP27A1 and HMG-CoA reductase. Basic Clin Pharmacol Toxicol100: 392–397.
35. S.GuethoffK.StroehC.GrinningerM.KoenigE.KleinertA.Rieger. (2015) De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation – 8-year results. J Heart Lung Transplant34: 634–642.
36. E.GyurusZ.KaposztasB.Kahan (2011) Sirolimus therapy predisposes to newonset diabetes mellitus after renal transplantation: a long term analysis of various treatment regimens. Transplant Proc43: 15831592.
37. G.HajerT.van HaeftenF.Visseren (2008) Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J29: 2959–2971.
38. C.HanevoldP.HoL.TalleyM.Mitsnefes (2005) Obesity and renal transplant outcome: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatrics115: 352–356.
39. H.HirschK.YakhontovaM.LuJ.Manzetti (2015) BK polyomavirus replication in renal tubular epithelial cells is inhibited by sirolimus, but activated by tacrolimus through a pathway involving FKBP-12. Am J Transplant doi: 10.1111/ajt.13541.
40. J.HjelmesaethA.HartmannJ.KofstadJ.StenstrømT.LeivestadT.Egeland. (1997) Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation64: 979–983.
41. B.HöckerL.WeberR.FenebergJ.DrubeU.JohnH.Fehrenbach. (2010) Improved growth and cardiovascular risk after late steroid withdrawal: 2-year results of a prospective, randomised trial in paediatric renal transplantation. Nephrol Dial Transplant25: 617–624.
42. L.HofbauerF.GoriB.RiggsD.LaceyC.DunstanT.Spelsberg. (1999) Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology140: 4382–4389.
43. H.HoldaasL.RostaingD.SerónE.ColeJ.ChapmanB.Fellstrøm. (2011) Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. Transplantation92: 410–418.
44. E.HoogeveenJ.AaltenK.RothmanJ.RoodnatM.MallatG.Borm. (2011) Effect of obesity on the outcome of kidney transplantation: a 20-year follow-up. Transplantation91: 869–874.
45. V.HoudeS.BrûléW.FestucciaP.BlanchardK.BellmannY.Deshaies. (2010) Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes59: 1338–1348.
46. B.HuangY.WangW.WangJ.ChenP.LaiZ.Liu. (2015) mTORC1 prevents preosteoblast differentiation through the notch signaling pathway. PLoS Genet11: e1005426.
47. A.HumarK.GillinghamR.KandaswamyW.PayneA.Matas (2007) Steroid avoidance regimens: a comparison of outcomes with maintenance steroids versus continued steroid avoidance in recipients having an acute rejection episode. Am J Transplant7: 1948–1953.
48. S.IngL.SinnottS.DonepudiE.DaviesR.PelletierN.Lane (2011) Change in bone mineral density at one year following glucocorticoid withdrawal in kidney transplant recipients. Clin Transplant25: E113–E123.
49. A.IsraniJ.SnyderM.SkeansB.Kasiske (2012) Clinical diagnosis of metabolic syndrome: predicting new-onset diabetes, coronary heart disease, and allograft failure late after kidney transplantation, Transplant Int25: 748–757.
50. S.JiménezR.MarcénC.VaamondeC.CaballeroA.Fernández-RodríguezJ.Villafruela. (2015) Bone fractures and lumbar mineral density after renal transplantation. A long-term cross-sectional study. Clin Transplant. DOI: 10.1111/ctr.12666.
51. O.JohnstonC.RoseA.WebsterJ.Gill (2008) Sirolimus is associated with newonset diabetes in kidney transplant recipients. J Am Soc Nephrol19: 14111418.
52. M.Juan KhongC.Ping Chong (2014) Prevention and management of new-onset diabetes mellitus in kidney transplantation. Neth J Med72: 127–134.
53. B.JulianD.LaskowJ.DubovskyE.DubovskyJ.CurtisL.Quarles (1991) Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med325: 544–550.
54. KDIGO (Kidney Disease: Improving Global Outcomes) Transplant Work Group (2009) KDIGO clinical practice guidelines for the care of kidney transplant recipients. Am J Transplant9: S1–S157.
55. S.KirinoJ.FukunagaS.IkegamiH.TsuboiM.KimataN.Nakata. (2004) Regulation of bone metabolism in immunosuppressant (FK506)-treated rats. J Bone Miner Metab22: 554–560.
56. M.KislikovaM.SerasE.MonfaE.RodrigoG.Fernandez-FresnedoJ.Ruiz. (2015) Number of antihypertensive drugs at 1 year after kidney transplantation. Transplant Proc47: 76–77.
57. M.KneisselN.Luong-NguyenM.BaptistR.CortesiS.Zumstein-MeckerS.Kossida. (2004) Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. Bone35: 1144–1156.
58. S.KnightP.Morris (2010) Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation89: 1–14.
59. S.KnightN.RussellL.BarcenaP.Morris (2009) Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation87: 785–794.
60. B.KrämerM.KlingerŠ.VítkoM.GlydaK.MidtvedtS.Stefoni. (2012) Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial. Transplantation94: 492–498.
61. K.LambS.LodhiH.Meier-Kriesche (2011) Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transpl11: 450–462.
62. G.LambertN.StraznickyE.LambertJ.DixonM.Schlaich (2010) Sympathetic nervous activation in obesity and the metabolic syndrome–causes, consequences and therapeutic implications. Pharmacol Ther126: 159–172.
63. D.LangsfordK.Dwyer (2015) Dysglycemia after renal transplantation: Definition, pathogenesis, outcomes and implications for management. World J Diabetes6: 1132–1151.
64. Y.Le MeurA.ThierryF.GlowackiJ.RerolleV.GarrigueN.Ouali. (2011) Early steroid withdrawal and optimization of mycophenolic acid exposure in kidney transplant recipients receiving mycophenolate mofetil. Transplantation92: 1244–1251.
65. Y.LebranchuA.ThierryO.ToupanceP.WesteelI.EtienneE.Thervet. (2009) Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant9: 1115–1123.
66. N.LloberasJ.TorrasG.AlperovichJ.CruzadoP.Giménez-BonaféI.Herrero-Fresneda. (2008) Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats. Nephrol Dial Transplant23: 3111–3119.
67. F.LuanD.SteffickO.Akinlolu (2011) New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. Transplantation91: 334–341.
68. Y.LuoP.RanaY.Will (2012) Cyclosporine A and palmitic acid treatment synergistically induce cytotoxicity in HepG2 cells. Toxicol Appl Pharmacol261: 172–180.
69. H.LysterG.PanickerN.LeaverN.Banner (2004) Initial experience with sirolimus and mycophenolate mofetil for renal rescue from cyclosporine nephrotoxicity after heart transplantation. Transplant Proc36: 3167–3170.
70. H.MallucheM.Monier-FaugereJ.Herberth (2010) Bone disease after renal transplantation. Nat Rev Nephrol6: 32–40.
71. R.Marcén (2009) Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs69: 2227–2243.
72. R.MarcénC.CaballeroJ.PascualJ.TeruelM.TenorioJ.Ocaña. (2006) Lumbar bone mineral density in renal transplant patients on neoral and tacrolimus: a four-year prospective study. Transplantation81: 826–831.
73. P.MassonL.HendersonJ.ChapmanJ.CraigA.Webster (2014) Belatacept for kidney transplant recipients. Cochrane Database Syst Rev11: CD010699.
74. A.Matas (2008) Steroid elimination-who, when, how?Transplant Proc40: S52–S56.
75. J.MoralesR.MarcénD.del CastilloA.AndresM.Gonzalez-MolinaF.Oppenheimer. (2012) Risk factors for graft loss and mortality after renal transplantation according to recipient age: a prospective multicentre study. Nephrol Dial Transplant27: iv39–iv46.
76. J.MorrisettG.Abdel-FattahB.Kahan (2003) Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc35: 143S–150S.
77. B.NankivellR.BorrowsC.FungP.O’ConnellJ.ChapmanR.Allen (2004) Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation78: 557–565.
78. B.NicolettoN.FonsecaR.ManfroL.GonçalvesC.LeitãoG.Souza (2014) Effects of obesity on kidney transplantation outcomes: a systematic review and meta-analysis. Transplantation98: 167–176.
79. L.OrdonezI.BernardM.ChabodJ.AugustoV.Lauwers-CancesC.Cristini. (2013) A higher risk of acute rejection of human kidney allografts can be predicted from the level of CD45RC expressed by the recipients’ CD8 T cells. PLoS One8: e69791.
80. E.O’ShaughnessyD.DahlC.SmithB.Kasiske (2002) Risk factors for fractures in kidney transplantation. Transplantation74: 362–366.
81. A.PadiyarJ.AugustineK.BodziakM.AederJ.SchulakD.Hricik (2010) Influence of African-American ethnicity on acute rejection after early steroid withdrawal in primary kidney transplant recipients. Transplant Proc42: 1643–1647.
82. L.PapeT.Ahlenstiel (2014) mTOR inhibitors in pediatric kidney transplantation. Pediatr Nephrol29: 1119–1129.
83. J.PascualA.RoyuelaC.GaleanoM.CrespoJ.Zamora (2012) Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review. Nephrol Dial Transplant27: 825832.
84. J.PascualJ.ZamoraC.GaleanoA.RoyuelaC.Querela (2009) Steroid avoidance or withdrawals for kidney transplant recipients. Cochrane Database Syst Rev4: CD007669.
85. S.PatelJ.KwanE.McCloskeyG.McGeeG.ThomasD.Johnson. (2001) Prevalence and causes of low bone density and fractures in kidney transplant patients. J Bone Miner Res16: 1863–1870.
86. M.PazJ.RobertiF.MosF.Cicora (2014) Conversion to belatacept-based immunosuppression therapy in renal transplant patients. Transplant Proc46: 2987–2990.
87. J.PazikM.OłdakZ.LewandowskiM.PodgórskaE.SitarekR.Płoski. (2013) Uridine diphosphate glucuronosyl transferase 2B7 variant p.His268Tyr as a predictor of kidney allograft early acute rejection. Transplant Proc45: 1516–1519.
88. A.PenfornisS.Kury-Paulin (2006) Immunosuppressive drug-induced diabetes. Diabetes Metab32: 539–546.
89. P.PennisiA.TrombettiE.GiostraG.MenthaR.RizzoliC.Fiore (2007) Pamidronate and osteoporosis prevention in liver transplant recipients. Rheumatol Int27: 251–256.
90. M.PereiraJ.PalmingM.RizellM.AurelianoE.CarvalhoM.SvenssonJ.Eriksson (2014) Cyclosporine A and tacrolimus reduce the amount of GLUT4 at the cell surface in human adipocytes: increased endocytosis as a potential mechanism for the diabetogenic effects of immunosuppressive agents. J Clin Endocrinol Metab99: E1885–E1894.
91. E.PeritoR.LustigP.Rosenthal (2016) Metabolic syndrome components after pediatric liver transplantation: prevalence and the impact of obesity and immunosuppression. Am J Transplant. DOI: 10.1111/ajt.13714.
92. V.PichetteA.BonnardeauxL.PrudhommeM.GagnéJ.CardinalD.Ouimet (1996) Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am J Kidney Dis28: 105–114.
93. E.PorriniP.DelgadoA.AlvarezM.CoboL.PérezJ.González-Posada. (2008) The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation. Nephrol Dial Transplant23: 1436–1441.
94. G.PourmandS.DehghaniM.RahmatiA.MehrsaiS.GooranF.Alizadeh. (2015) Does hypertension remain after kidney transplantation?Acta Med Iran53: 297–300.
95. E.RazeghiM.ShafipourH.AshrafG.Pourmand (2011) Lipid disturbances before and after renal transplant. Exp Clin Transplant9: 230–235.
96. M.Rodríguez-MoránF.Guerrero-Romero (2011) Insulin secretion is decreased in non-diabetic individuals with hypomagnesaemia. Diabetes Metab Res Rev27: 590–596.
97. A.RossiJ.Vella (2015) Hypertension, living kidney donors, and transplantation: where are we today?Adv Chronic Kidney Dis22: 154–164.
98. L.RostaingP.MassariV.GarciaE.Mancilla-UrreaG.NainanM.del Carmen Rial. (2011) Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol6: 430–439.
99. L.RostaingF.VincentiJ.GrinyóK.RiceB.BresnahanS.Steinberg. (2013) Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant13: 2875–2883.
100. N.RostambeigiI.LanzaP.DzejaM.DeedsB.IrvingH.Reddi. (2011) Unique cellular and mitochondrial defects mediate FK506-induced islet β-cell dysfunction. Transplantation91: 615–623.
101. D.Rush (2013) The impact of calcineurin inhibitors on graft survival. Transplant Rev (Orlando)27: 93–99.
102. R.SaidiJ.ChangS.VerbS.BrooksI.NalbantogluV.Adsay. (2007) The effect of methyl prednisolone on warm ischemia-reperfusion injury in the liver. Am J Surg193: 345–347.
103. M.SanderT.LysonG.ThomasR.Victor (1996) Sympathetic neural mechanisms of cyclosporine-induced hypertension. Am J Hypertens9: 121S–138S.
104. S.SandriniN.AslamR.TardanicoG.SettiN.BossiniF.Valerio. (2012) Tacrolimus versus cyclosporine for early steroid withdrawal after renal transplantation. J Nephrol25: 43–49.
105. S.SchmidtS.HamannJ.LangrehrC.HöflichJ.MittlerD.Jacob. (2007) Preoperative high-dose steroid administration attenuates the surgical stress response following liver resection: results of a prospective randomized study. J Hepatobiliary Pancreat Surg14: 484–492.
106. J.ScholdE.PoggioD.GoldfarbL.KaylerS.Flechner (2015) Clinical outcomes associated with induction regimens among retransplant kidney recipients in the United States. Transplantation99: 1165–1171.
107. T.SchweerW.GwinnerI.ScheffnerA.SchwarzH.HallerC.Blume (2014) High impact of rejection therapy on the incidence of posttransplant diabetes mellitus after kidney transplantation. Clin Transplant28: 512519.
108. A.SharifK.Baboolai (2011) Complications associated with new-onset diabetes after kidney transplantation. Nat Rev Nephrol8: 34–42.
109. I.SoveriJ.SnyderH.HoldaasI.HolmeA.JardineG.L’Italien. (2013) The external validation of the cardiovascular risk equation for renal transplant recipients: applications to BENEFIT and BENEFIT-EXT trials. Transplantation95: 142–147.
110. G.SpinelliC.FelipeS.ParkE.Mandia-SampaioH.Tedesco-SilvaJ.Medina-Pestana (2011) Lipid profile changes during the first year after kidney transplantation: risk factors and influence of the immunosuppressive drug regimen. Transplant Proc43: 3730–3737.
111. C.StaatzL.GoodmanS.Tett (2010) Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet49: 141–175.
112. P.StrattaM.QuagliaT.CenaR.AntoniottiR.FenoglioA.Menegotto. (2012) The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation. Eur J Clin Pharmacol68: 671–680.
113. N.SugiokaT.KokuhuM.OkamotoN.YoshimuraY.ItoN.Shibata. (2006) Effect of plasma lipid on pharmacokinetics of ciclosporin and its relationship with plasma prednisolone level in renal transplant patients. J Pharm Pharmacol58: 1193–1200.
114. H.SukC.ZhouT.YangH.ZhuR.YuO.Olabisi. (2013) Ablation of calcineurin Aβ reveals hyperlipidemia and signaling cross-talks with phosphodiesterases. J Biol Chem288: 3477–3488.
115. D.TaberH.MeadowsN.PilchK.ChavinP.BaligaL.Egede (2013) The impact of diabetes on ethnic disparities seen in kidney transplantation. Ethn Dis23: 238–244.
116. H.TakeuchiN.MatsunoT.HiranoM.GulimireK.HamaY.Nakamura. (2011) Steroid withdrawal based on lymphocyte sensitivity to endogenous steroid in renal transplant recipients. Biol Pharm Bull34: 1578–8153.
117. M.TerjimanianC.HarbaughA.HussainK.OlugbadeS.WaitsS.Wang. (2015) Abdominal adiposity, body composition and survival after liver transplantation. Clin Transplant doi: 10.1111/ctr.12688.
118. G.TessariG.Girolomoni (2012) Nonmelanoma skin cancer in solid organ transplant recipients: update on epidemiology, risk factors, and management. Dermatol Surg38: 1622–1630.
119. A.TeutonicoP.SchenaS.Di Paolo (2005) Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol16: 31283135.
120. K.TornatoreD.BiocevichK.ReedK.TousleyJ.SinghR.Venuto (1995) Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. Transplantation59: 649–795.
121. M.TurgayF.TurgayE.DevrimO.KucuksahinM.CaydereI.Durak (2012) The effects of dexamethasone on oxidant/antioxidant status in kidneys of rats administered mercuric chloride. Bratisl Lek Listy113: 10–13.
122. S.UpalaT.PanichsillapakitK.WijarnpreechaV.JaruvongvanichA.Sanguankeo (2015) Underweight and obesity increase the risk of mortality after lung transplantation: a systematic review and meta-analysis. Transpl Int. DOI: 10.1111/tri.12721 [Epub ahead of print].
123. S.VadlamudiB.HiremagalurL.TaoS.KalhanR.KalariaH.Kaung. (1993) Long-term effects on pancreatic function of feeding a HC formula to rats during the preweaning period. Am J Physiol265: E565–E571.
124. M.VerouxT.TallaritaD.CoronaN.SinagraA.GiaquintaD.Zerbo. (2013) Conversion to sirolimus therapy in kidney transplant recipients with new onset diabetes mellitus after transplantation. Clin Dev Immunol2013: 496974.
125. U.VesterA.SchaeferB.KranzA.WingenS.NadalinA.Paul. (2005) Development of growth and body mass index after pediatric renal transplantation. Pediatr Transplant9: 445–449.
126. F.VincentiF.SchenaS.ParaskevasI.HauserR.WalkerJ.Grinyo (2008) A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant8: 307–316.
127. R.WangY.XuJ.WuY.WangQ.HeJ.Chen (2013) Reduced-dose cyclosporine with mycophenolate mofetil and prednisone significantly improves the long-term glomerular filtration rate and graft survival. Intern Med52: 947–953.
128. N.WebbS.DouglasA.RajaiS.RobertsR.GrendaS.Marks. (2015) Corticosteroid-free kidney transplantation improves growth: 2-year follow-up of the TWIST randomized controlled trial. Transplantation99: 1178–1185.
129. A.WebsterL.RusterR.McGeeS.MathesonG.HigginsN.Willis. (2010) Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev1: CD003897.
130. A.WebsterR.WoodroffeR.TaylorJ.ChapmanJ.Craig (2005a) Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. BMJ331: 810.
131. A.WebsterR.WoodroffeR.TaylorJ.ChapmanJ.Craig (2005b) Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev4: CD003961.
132. M.WeirE.BurgessJ.CooperA.FenvesD.GoldsmithD.McKay. (2015) Assessment and management of hypertension in transplant patients. J Am Soc Nephrol26: 1248–1260.
133. J.WeisingerR.CarliniE.RojasE.Bellorin-Font (2006) Bone disease after renal transplantation. CJASN1: 1300–1313.
134. K.WjidanE.IbrahimB.CaszoJ.GnanouH.Singh (2015) Dysregulation of glucose homeostasis following chronic exogenous administration of leptin in healthy Sprague-Dawley rats. J Clin Diagn Res9: OF06–9.
135. E.WoodleM.FirstJ.PirschF.ShihabA.GaberP.Van Veldhuisen (2008) A prospective, randomized, doubleblind, placebocontrolled multicenter trial comparing early (7 day) corticosteroid cessation versus longterm, lowdose corticosteroid therapy. Ann Surg248: 564577.
136. B.YaoX.ChenF.ShenW.XuT.DongL.Chen. (2013) The incidence of posttransplantation diabetes mellitus during follow-up in kidney transplant recipients and relationship to Fok1 vitamin D receptor polymorphism. Transplant Proc45: 194–196.
137. K.YongH.NguyenL.HiiD.ChanN.BoudvilleA.Messineo. (2013) Association of a change in immunosuppressive regimen with hemodynamic and inflammatory markers of cardiovascular disease after kidney transplantation. Am J Hypertens26: 843–849.
138. X.ZhangH.HuangS.HanS.FuL.Wang (2013) Is it safe to withdraw steroids within seven days of renal transplantation?Clin Transplant27: 1–8.
139. L.Zsom, L.Wagner, T.Fülöp (2015) Minimization vs tailoring: Where do we stand with personalized immunosuppression during renal transplantation in 2015? World J Transplant 5: 73–80.